ReviewMolecules (Basel, Switzerland)2020
Photoactivatable Platinum-Based Anticancer Drugs: Mode of Photoactivation and Mechanism of Action.
Review in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 45 citations in OpenAlex.
- Bacterial Ghosts as Innovative Transport Vehicles for Platinum-Based Anticancer Drugs.ChemMedChem · 2026Article
- Excited-StateInorganic chemistry · 2025Article
- Anticancer Activity of Metallodrugs and Metallizing Host Defense Peptides-Current Developments in Structure-Activity Relationship.International journal of molecular sciences · 2024Review
- Sequential dual-locking strategy using photoactivated Pt(IV)-based metallo-nano prodrug for enhanced chemotherapy and photodynamic efficacy by triggering ferroptosis and macrophage polarization.Acta pharmaceutica Sinica. B · 2024Article
- Unraveling Light-Activated Insulin Action in Regulating Blood Glucose: New Photoactivatable Insight as a Novel Modality in Diabetes Management.Molecules (Basel, Switzerland) · 2024Article
- A Conformationally Restricted Gold(III) Complex Elicits Antiproliferative Activity in Cancer Cells.Inorganic chemistry · 2023Article
- Visible light-activatable platinum(IV) prodrugs harnessing CD36 for ovarian cancer therapy.Dalton transactions (Cambridge, England : 2003) · 2023Article
- Stimuli-responsive nanocarrier delivery systems for Pt-based antitumor complexes: a review.RSC advances · 2023Review
- Synthesis, Characterization and Photoactivation Studies on the Novel Pt(IV)-Based [Pt(OCOCHInternational journal of molecular sciences · 2023Article
- Recent Advances in Light-Controlled Activation of Pt(IV) Prodrugs.International journal of molecular sciences · 2022Review
- Development of Photoremovable Linkers as a Novel Strategy to Improve the Pharmacokinetics of Drug Conjugates and Their Potential Application in Antibody-Drug Conjugates for Cancer Therapy.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Ligand Evolution in the Photoactivatable Platinum(IV) Anticancer Prodrugs.Frontiers in chemistry · 2022Review
- Single-Cell Chemistry of Photoactivatable Platinum Anticancer Complexes.Journal of the American Chemical Society · 2021Article
- Unraveling the Photodynamic Activity of Cationic Benzoporphyrin-Based Photosensitizers against Bladder Cancer Cells.Molecules (Basel, Switzerland) · 2021Article
- Oxaliplatin-Induced Neuropathy: Genetic and Epigenetic Profile to Better Understand How to Ameliorate This Side Effect.Frontiers in molecular biosciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Platinum-based anticancer drugs are a class of widely used agents in clinical cancer treatment. However, their efficacy was greatly limited by their severe side effects and the arising drug resistance. The selective activation of inert platinum-based drugs in the tumor site by light irradiation is able to reduce side effects, and the novel mechanism of action of photoactivatable platinum drugs might also conquer the resistance. In this review, the recent advances in the design of photoactivatable platinum-based drugs were summarized. The complexes are classified according to their mode of action, including photoreduction, photo-uncaging, and photodissociation. The rationale of drug design, dark stability, photoactivation process, cytotoxicity, and mechanism of action of typical photoactivatable platinum drugs were reviewed. Finally, the challenges and opportunities for designing more potent photoactivatable platinum drugs were discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.